Program
Ethanol
Also written as “Alcohol”, “Dehydrated Alcohol Injection, USP” and “hand antiseptic with CHG and alcohol”.
Its studies are mostly in Essential Hypertension · Hypertension · Driving Under the Influence · Sleep Initiation and Maintenance Disorders · Fasting, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ablative Solutions | 32 open or running | phase 3since Sep 16, 2016 | Sep 16, 2016 | May 2028phase 3 · NCT07083765 |
| american-medical-systems | 10 open or running | phase 2since May 15, 2002 | May 15, 2002 | none ahead |
| Orfagen | 10 open or running | phase 2since Apr 16, 2007 | Apr 16, 2007 | none ahead |
Also a collaborator on its studies: 3m, Knoa Pharma and benu-biopharma-llc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 15, 2002First study: phase 2 study in Prostatic DiseasesNew to american-medical-systemsamerican-medical-systems · NCT00037141 · 150 enrolled
- Apr 16, 2007Orfagen's first study: phase 2 study in Congenital Venous MalformationNew to OrfagenOrfagen · NCT00462462 · 32 enrolled · United States, France
- Sep 16, 2016Ablative Solutions's first study: phase 3 study in HypertensionNew to Ablative SolutionsAblative Solutions · NCT02910414 · 300 enrolled · United States
- Mar 23, 2018Phase 2 study in HypertensionAblative Solutions · NCT03503773 · 350 enrolled · Belgium, France, Germany and more
- May 12, 2025Phase 3 study in HypertensionAblative Solutions · NCT07083765 · 202 planned · United States
Ahead
- May 2028Primary completion: phase 3 study in HypertensionAblative Solutions · NCT07083765
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07083765Hypertension · United States | 3 | Not yet recruiting | Ablative Solutions | May 2028 | 202 |
| NCT03503773Hypertension · Belgium, France, Germany and more | 2 | Completed | Ablative Solutions | Jan 31, 2022 | 350 |
| NCT02910414Hypertension · United States | 3 | Active, not recruiting | Ablative Solutions | Dec 2023 | 300 |
| NCT00462462Congenital Venous Malformation · United States, France | 2 | Completed | Orfagen | Jun 2010 | 32 |
| NCT00037141Prostatic Diseases | 2 | Completed | american-medical-systems | 150 |
How it is read
Names in the registry
- “Ethanol”, 4 entries
- “Alcohol”, 3 entries
- “Dehydrated Alcohol Injection, USP”, 1 entry
- “hand antiseptic with CHG and alcohol”, 1 entry
- “Dehydrated alcohol”, 1 entry
Conditions, from the studies’ own filings
- Essential Hypertension, 2 studies
- Hypertension, 1 study
- Driving Under the Influence, 1 study
- Sleep Initiation and Maintenance Disorders, 1 study
- Fasting, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.